| HOME >> BIOLOGY >> TECHNOLOGY |
Since 2004, Lord Moonie has served as a non-executive director of AEA Technology, which provides a wide range of consultancy and advisory services, and program management to government in the fields of energy management and the environment.
Lord Moonie is a member of the Board of Trustees of the charity Skillforce, and is a consultant in a variety of fields, including energy, health services and communications. He currently sits on the European Advisory Board of Northrop Grumman and is a non-executive director of Party Gaming.
About PharmAthene, Inc.
PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:
-- SparVax(TM) -- a second generation recombinant protective antigen (rPA) anthrax vaccine
-- Valortim(R) -- a fully human monoclonal antibody for the prevention and treatment of anthrax infection
-- Protexia(R) -- a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents
-- RypVax(TM) -- a recombinant dual antigen vaccine for plague a third generation rPA anthrax vaccine.
For more information about PharmAthene, please visit http://www.PharmAthene.com.
Statement on Cautionary Factors
Except for the historical information presented herein, matters
discussed may constitute forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 that are subject to
certain risks and uncertainties that could cause ac
'/>"/>
| SOURCE PharmAthene, Inc. Copyright©2008 PR Newswire. All rights reserved |